|Biotech partner:||Vernalis (UK)|
|Pharma Partner:||Servier (France)|
|Type of agreement:||* R&D
|Nature of the agreement:||Vernalis and Servier have announced the extension of their ongoing oncology collaboration following success during its initial three-year term (See agreements).
As previously announced in May 2007, this collaboration focuses on two undisclosed oncology targets.